CTIF

Across TCGA pan-cancer cohorts, CTIF RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CTIF data layer compared with 5 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CTIF RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CTIF expression acts as an unfavorable survival marker, although some lineages such as LGG and PAAD show a favorable association.

BLCA, UVM, and LGG are the cancer types where CTIF RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Quartile	All	0.335	0.632	<.001	71	view →
UVM	DFS	Median	All	0.427	0.727	<.001	58	view →
LGG	DFS	Median	All	0.897	0.766	<.001	46	view →
LUSC	OS	Median	All	0.340	0.665	<.001	45	view →
ACC	DFS	Tertile	All	0.265	0.728	<.001	30	view →
THCA	DFS	Median	IV	0.472	0.891	.018	15	view →
PAAD	OS	Tertile	All	0.457	0.258	.008	15	view →
LUAD	DFS	Quartile	IV	0.504	0.906	.015	14	view →
KIRC	DFS	Tertile	All	0.866	0.723	.017	14	view →
SCLC	DFS	Tertile	II,III,IV	0.825	0.321	.006	13	view →
MESO	DFS	Median	IV	0.186	0.524	.004	12	view →
HNSC	OS	Median	All	0.616	0.791	.006	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CTIF–BLCA (OS)

Open the BLCA breakdown →